肾脏嫌色细胞癌 (附3例报告)

肾脏嫌色细胞癌是一种较少见的肾细胞癌 ,对其临床特点、病理学特征了解不多。我院从 1 999年至今共收治肾脏嫌色细胞癌 3例 ,结合文献报告如下。1　病例报告例 1　女 ,45岁。 5年前体检时发现右肾占位性病变 ,约 3ｃｍ× 2ｃｍ大小 ,ＣＴ示错构瘤可能。近半个月前感腰酸 ,再次复查ＣＴ示肿块增大至 5ｃｍ× 4ｃｍ。入院后Ｂ超示右实质性占位病变。术中所见 :肾中极腹侧约 4ｃｍ× 4ｃｍ× 3ｃｍ肿块 ,突出肾外。行右肾肿瘤剜出术。肿块切面灰黄色 ,呈均质状。术中冷冻切片病理诊断为嗜酸细胞瘤。术后石蜡切片病理诊断为肾脏嫌色细胞癌。例 …     

肾嫌色细胞癌的临床研究

目的 探讨肾嫌色细胞癌的临床特点,提高肾嫌色细胞癌的诊断和治疗水平.方法 针对1例肾嫌色细胞癌的临床资料,结合相关文献进行分析.结果 病理结果示为肾嫌色细胞癌.免疫组化:CK部分细胞(+),CD10(-),CK8(+),RCC(-),vimentin(-),Ki-67(＜5%+),Hale胶状铁染色(+).结论 肾嫌色...     

肾嫌色细胞癌的诊断和治疗（附五例报告）

目的 提高肾嫌色细胞癌的诊治水平。方法 回顾性分析5例肾嫌色细胞癌资料,结合文献复习进行讨论。结果 3例肾部分切除术,2例行根治性肾切除术,随访个月至4年,4例无瘤存活,1例于术后1年死于中风。结论 肾嫌色细胞癌是一种低度恶性的肾细胞癌,确诊有赖于影像学检查及典型病理表现,治疗以手术为主。     

肾嫌色细胞癌临床特征分析

目的 探讨肾嫌色细胞癌的临床特点并分析其预后.方法 对1998年1月至2008年1月期间收治的29例肾嫌色细胞癌患者的临床资料包括临床表现、影像学检查、治疗方法、Ptnm分期和生存期随访等,进行回顾性分析.结果 所有29例患者均缺乏典型的临床症状,术前影像学检查亦未发现特异性表现.23例患者行根治性肾切除术,6例行保留肾单位手术(NSS),病理分期:Pt1n0m0 11例,Pt2n0m0 8例,pT3aN0M0 5例,Pt1nm0 3例,Pt2n1m0 2例.26例患者获得随访,随访24～144个月,平均90个月;3例死于心脑血管疾病,6例局部复发后4例再次手术,1例远处转移,21例无瘤生存.与同期肾透明细胞癌患者相比,累积5年生存率两者分别为83.9%和63.8%,差异无统计学意义(P＞0.05),累积10年生存率分别为77.9%和49.9%,差异具有统计学意义(P＜0.01).结论 肾嫌色细胞癌是一种少见的具有特殊形态的肾细胞癌病理亚型,主要通过病理学予以鉴别诊断,手术切除是治疗初发或复发的肾嫌色细胞癌的首选方法,其预后较好.

Abstract：

Objectives To explore the clinical, pathological features and prognosis of patients with chromophobe renal cell carcinoma. Methods From January 1998 to January 2008, clinical data of 29 patients with chromophobe renal cell carcinoma including clinical manifestations, imaging examinations,treatment models, pTNM stages and follow-up results, were summarized to investigate its features and prognosis. Results All cases had no obvious clinical and preoperative imaging presentation. There were 23 patients underwent radical nephrectomy, and 6 cases underwent nephron sparing surgery. Postoperative pathological findings confirmed the diagnosis of chromophobe renal cell carcinoma. Macroscopically, the cut surface of the tumors were generally beige in color. Histologically, it showed polygonal chromophobe cells and small round eosinophilic cells with eccentric hyaline degeneration. These tumor cells had a clear and sharp membrane, lightly stained abundant cytoplasm with a fine reticular translucent pattern and irregular nuclei. And a perinuclear halo was often seen in these cells. Histochemically, the tumor cells generally show a diffuse and strong reaction for CK-8 with a negative expression of Vimentin. The pTNM stages of the tumor were as follows, pT1N0M0 in 11 cases, pT2N0M0 in 8 cases, pT3aN0M0 in 5 cases, pT1N1M0 in 3 cases,pT2N1M0 in 2 cases. Twenty-six cases of patients were followed up (24 to 144 months, with an average of 90 months), 3 cases died of cardio-cerebrovascular disease, and local recurrence involved in 6 cases with reoperation in 4 cases, as well as distant metastasis in 1 case. Twenty-one cases survived with tumor-free.The statistical results indicated that the survival rates of the patients with chromophobe renal cell carcinoma in five years and ten years were 83.9%, 77.9%, respectively, compared with renal cell carcinoma of the same stage 63. 8% and 49. 9% at the same periods, and there is no difference in the survival rate of five years( P ＞ 0. 05 ) but significant difference in that of ten years ( P ＜ 0. 01 ). Conclusions Chromophobe renal cell carcinoma is a morphologically uncommon subtype of renal cell carcinoma with the good prognosis. Definite diagnosis depends on its typical pathological feature. Radical nephrectomy is the first choice for the treatment of chromophobe renal cell carcinoma.     

肾嫌色细胞癌临床与病理学特点分析

目的探讨肾嫌色细胞癌的临床及病理学特点，提高对此病的诊治水平。方法总结19例肾嫌色细胞癌患者的临床及病理资料。男10例，女9例。平均年龄53岁。左侧9例，右侧10例。偶发12例，7例有肉眼血尿、腰痛不适和腹部包块等症状。结果B超主要表现为包膜完整的低回声肿块。CT扫描肿瘤多为均匀低密度，边界清晰。肿瘤平均直径8．2cm。TNM分期T1N0M0 8例，T2N0M0 11例。行根治性肾切除17例，肾部分切除2例。16例获得随访，随访时间3个月～16年，平均无瘤生存4．8年。病理特点：肿瘤大体标本多为均匀深棕色实体，1例瘤体中央有纤维瘢痕；光镜下瘤细胞由典型型和嗜酸型两种细胞组成，胞膜清晰；免疫组化检测CK8阳性、Vimentin阴性；Hale胶体铁染色阳性；电镜下胞质内有大量膜性小空泡。结论肾嫌色细胞癌具有独特的形态学特点。B超、CT检查缺乏特异性。多数病例瘤体较大，但TNM分期多为早期，预后良好。     

104例肾嫌色细胞癌的临床分析

目的 探讨肾嫌色细胞癌的临床特点、治疗方式的选择及患者预后生存情况。方法回顾性分析陆军军医大学第二附属医院2012年1月至2022年1月收治的104例经术后病理诊断为肾嫌色细胞癌(chRCC)的患者临床资料。所有患者均行手术治疗,对患者的影像学资料、病理资料及术后生存情况进行分析和总结。结果 104例患者中有67例行CT检查,报告显示平扫期多数呈等密度或稍高密度软组织影,肿瘤内若存在坏死灶,则可能出现混杂密度影,部分肿瘤内有钙化,增强期大多呈现轻度或中度不均匀强化;4例行MRI检查,强化时均呈不均匀强化,静脉期强化均减退;病理结果示chRCC主要包括两种细胞类型,一种为体积较大的多角形半透明细胞,另一种为小圆形的嗜酸性细胞。8例患者失访,3例患者因非肾肿瘤性疾病死亡,2例因转移死亡,其余患者均长期生存,预后良好。结论 chRCC临床症状不典型,超声可作为首选体检筛查手段,CT和MRI检查在chRCC诊断上也具有一定优势。手术为早期chRCC首选治疗方案,多数患者预后良好,极少数患者术后出现转移或复发。晚期chRCC目前尚无统一治疗方案。     

肾嫌色细胞癌影像学特点与外科治疗选择

目的 提高肾嫌色细胞癌的临床诊治水平. 方法 回顾性分析25例肾嫌色细胞癌患者临床资料.男13例、女12例,平均年龄51岁.左侧13例,右侧12例.无症状肾癌16例,有腰部不适、发热、肉眼血尿等症状9例.实验室检查发现肝功能异常1例、红细胞沉降率加快1例.结合文献复习讨论肾嫌色细胞癌的影像学特点与外科治疗选择. 结果 B超检查肿瘤主要表现为低回声、有包膜、血流信号不明显.CT及MRI扫描肿瘤特征为边界清楚、质地均匀(CT平扫为70%、MR为73%),出血、坏死和囊性变少见,增强扫描多为均匀强化(CT为65%、MR为67%)及轻度强化(CT为65%、MR为93%).肿瘤直径＞4.0 cm的22例患者行根治性肾切除术、≤4.0 cm且位于肾周边的3例行肾部分切除术.肿瘤平均直径7.6 cm,剖面质地多均匀、呈灰白色或暗红色,光镜下癌细胞呈板状或条索状排列、胞质苍白或呈嗜酸性,免疫组化染色Vimentin阴性、CK18阳性.TNM分期pT1a 8例、pT1b 9例、pT2 6例、pT3a 2例.23例获随访,平均随访28个月,无瘤生存22例,1例于术后58个月发现肺转移,经干扰素-α治疗、吉西他滨及氟尿嘧啶化疗3个月后死亡. 结论 肾嫌色纽胞癌患者多无症状、分期较早.MR和CT主要表现为边界清楚、质地均匀、强化不明显.手术方式选择应遵循肾癌的外科治疗原则.患者预后多良好,手术至出现转移的时间间隔较长,建议延长术后随访时间.     

127例肾嫌色细胞癌免疫组化分析

目的研究肾嫌色细胞癌(Renal chromophobe cell carcinom)的免疫组化特点,并从病理学角度探讨诊断肾嫌色细胞癌的分子标记物特点,以提高肾嫌色细胞癌的诊治水平。方法回顾性分析郑州大学第一附属医院收治的127例病理确诊为肾嫌色细胞癌的病理资料,分析其免疫组化特点,并复习相关文献。结果 127例病理确诊为肾嫌色细胞癌的免疫组化表达如下:S-100(11/98,11.2%),CK(111/113,98.2%),CK7(84/108,77.8%),CD10(52/109,47.7),CD117(105/111,94.6%),PAX-2(30/109,27.5%),PAX-8(79/96,82.3%),Vim(26/103,25.2%),EMA(103/104,99.0%),RCC(22/98,22.4%),Ki-67(6/111,5.4%),E-caderin(94/100,94.0%)。结论免疫标志物CK,CK7,EMA,E-caderin阳性及Vim,S-100阴性是肾嫌色细胞癌诊断的良好标记物。S-100A1的阴性表现还预示着肾嫌色细胞癌可能预后较好。CD117在肾嫌色细胞癌的细胞膜上的过表达可能是激酶抑制剂的潜在靶标,不过疗效仍需更多的研究证实。     

肾嫌色细胞癌的诊治（附4例报告）

目的 提高肾嫌色细胞癌的诊治水平。方法 回顾性分析4例肾嫌色细胞癌患者的临床资料。男3例，女1例，年龄34—76岁，平均52岁。结果 3例患者行肾癌根治术，1例行肾部分切除术。术后病理诊断为肾嫌色细胞癌，病理分期：pT1aNxMo 1例，pT1bNoMo3例。病理分级：G1 3例，G2 1例。免疫组织化学染色：CK8（低分子量细胞角蛋白）阳性，Vimentin（波型蛋白）阴性，Hale胶体铁阳性。随访4个月至8年，平均4年。4例患者均健在，无肿瘤复发或转移。结论 肾嫌色细胞癌是一种低度恶性的肾细胞癌，影像学检查对其诊断有重要帮助，确诊有赖于组织病理学检查，手术治疗后预后较好。     

肾嫌色细胞癌的超声造影表现

目的 分析肾嫌色细胞癌的超声造影特征,提高对该肿瘤的识别.方法 分析经手术病理证实的28例嫌色细胞癌超声造影资料,分析血供情况及造影特征,并进行时间-强度曲线参数分析.结果 28例嫌色细胞癌与肾皮质作参照均呈乏血供造影表现,且肿块呈不均匀增强,肿块局部呈"快进快出"造影表现,强化程度低于周围肾皮质,其中15例(54%)病灶内可出现辐射样分布的强回声带.时间-强度曲线显示嫌色细胞癌组曲线达峰绝对值、曲线下面积低于肾皮质(P＜0.05),造影剂到达时间、达峰时间、曲线上升支斜率高于肾髓质组(P＜0.05).结论 超声造影检查中,肾嫌色细胞癌瘤体内辐射状增强和瘤体呈乏血供型增强为诊断提供了依据.

Abstract：

Objective To discuss the imaging characteristics of chromophobic cell renal carcinoma (CCRC) and study the features on the contrast-enhanced ultrasound (CEUS). Methods The CEUS features of CCRC in 28 cases identified by pathology were reviewed. The blood supply and enhancement characteristic were observed and analyzed on time intensity curve parameters. Results The 28 cases of CCRC showed poor blood supply in contrast with the renal cortex. The CCRC presented with heterogeneity enhancement, part of the tumor took on a high wash-in and wash-out, and enhanced less intense than the surrounding renal cortex. The actinomorphous strong echo of the tumors might be revealed with CEUS in 15 cases (54%). The time intensity curve analysis demonstrated that the CCRCs' difference of peak intensity and area under the curve were lower than the renal cortex (P＜0.05), but arrival time, time-to-peak and slope of ascending curve were higher than the renal medulla (P＜0.05). Conclusion The actinomorphous enhancement and poor blood supply in the tumor of CEUS could provide diagnostic evidence for CRCC.     

A rare case of synchronous association of chromophobe renal cell carcinoma with urothelial carcinoma of urinary bladder

Introduction

Chromophobe renal cell carcinoma accounts for 3–5% of all RCCs. However, its association with urothelial carcinoma of urinary bladder has never been reported. We report a case of synchronous association of chromophobe RCC with low grade urothelial carcinoma of urinary bladder.

误诊为肾细胞癌的肾错构瘤临床分析(附5例报告)

目的：分析肾错构瘤(Hamartoma of kidney,HK)的影像学误诊原因,探讨如何避免其误诊。方法：回顾性分析35例HK及其5例误诊为肾细胞癌(RCC)的临床表现及影像学特点。结果：影像学误诊为肾癌5例。B超、CT、MRI和选择性肾动脉造影等检查上有相应的表现。结论：只根据影像学所见可发生误诊,应结合临床表现并综合分析各种影像学检查结果,可提高HK的术前诊断率。     

Renal cell carcinoma: case report and literature review

Renal cell carcinoma arising from epithelial cells of the renal tubule is a highly aggressive and malignant tumor in all ages. Less than 2% of cases occur in childhood, relatively in older age group. Only a few pediatric series have been presented in the English literature. Tumor is presented with characteristic findings of flank pain, gross hematuria, and palpable mass. Although one half of the patients have metastasis at the time of diagnosis, most cases are currently being incidentally detected using improved imaging techniques. The overall prognosis in children appears to be similar to that in adults. Tumor stage and complete surgical resection have been reported as the most meaningful prognostic factors for the outcome. The incidence of metastatic disease is same as in adults. The effect of chemotherapy and immunotherapy, either preoperatively or postoperatively, is unclear. Cure is the most likely consequence in localized and completely resected tumors. Here, we present an 8-year-old boy with renal cell carcinoma demonstrating only hematuria without any pathological physical examination findings. The mass was described by abdominal ultrasonography and computed tomography in the left kidney. After the left nephroureterectomy, the patient was given no therapy.     

Renal cell carcinoma (RCC) and telomerase activity: relationship to stage

Limited information is available on the correlation of telomerase activity and the clinical and pathological characteristics, in patients with renal cell carcinoma (RCC). Telomerase repeat amplification protocol (TRAP) was used to measure telomerase activity in frozen RCC specimens from partial/radical nephrectomies performed between 1987 and 1991. Presence of tumor tissue was verified by a pathologist using hematoxylin and eosin stained sections. RNA was measured to ensure the presence of intact protein necessary for telomerase expression. Data on demographics, tumor type, and stage at presentation, local recurrence, distant metastasis, disease-free survival (DFS), and overall survival (OS) was collected, and telomerase activity was correlated with each of these variables. Forty-nine of 67 patients (73%) were telomerase positive (+ve). Gender and stage were the only variables that appeared to be associated with telomerase positivity. Tumors were telomerase +ve in 12/21 females (57 %) vs. 37/46 males (80%) (P = 0.07). Tumors were telomerase +ve in 85% of Stage IV, 76% of Stage III, and 70% of Stage I/II patients (P = 0.12). Five-year survival was 0% for Stage IV, 57% for Stage III, and 77% for Stage I/II patients (P < 0.001), DFS 54% for stage III and 84% for Stage I/II patients (P = 0.05). Telomerase activity, however, was not related to survival in either univariate or multivariate analysis. In patients with telomerase +ve tumors 5-year survival was 55%, and with telomerase −ve tumors 58% (P = 0.56). Stage was the only variable associated with OS or DFS in clear cell RCC patients. In patients with advanced disease, there is a high incidence of telomerase positivity was found, within this limited sample, however, no correlation with survival was found.     

马蹄肾合并肾细胞癌3例报告

目的:提高马蹄肾合并肾细胞癌的认知水平。方法:报告3例马蹄肾合并肾细胞癌的临床表现、诊治过程及影象学特点。3例患者中,2例存在反复发生的泌尿系感染,2例合并结石,其中1例有明显的腰部绞痛病史。2例符合根治手术的病例行开放性根治性肾切除术。1例因存在远处转移而仅行生物治疗。结果:2例手术患者随访1年内,未发现肿瘤复发及转移。1例因放弃治疗而于半年内死于肿瘤转移。结论:对于符合根治手术条件的马蹄肾合并肾细胞癌患者,首选的治疗仍为根治性肾切除术。术前充分估计相应的变异血管,细致的腹膜后腔解剖,以及妥善处理峡部,是手术治疗的关键所在。     

Chromophobe renal cell carcinoma in an 18-year-old female

Renal cell carcinoma (RCC) in young adults is uncommon. Whether they have different clinicopathologic characteristics and outcomes from those in older patients is still a conflicting matter. In this article we present an uncommon subtype of RCC which is chromophobe RCC (chRCC) in a female aged less than 20 years.